Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<IPO>Hengrui Pharma (600276.SH) Applies for HK Listing
Recommend 14 Positive 14 Negative 4 |
||||
|
||||
|
A-share pharma leader Hengrui Pharma (600276.SH) has submitted a listing application to the Hong Kong Stock Exchange. Its joint sponsors are Morgan Stanley, Citi, and Huatai International. As an innovative pharma company in China, Hengrui Pharma strategically focuses on comprehensive therapeutic areas with significant unmet medical needs and growth potential. These mainly include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Last year, the company's revenue for 9M24 increased by 18.7% YoY to RMB20.189 billion, while profit attributable to the parent company grew by 33.8% to RMB4.62 billion. Zhong Huijuan, who controls the Hong Kong blue-chip pharma stock HANSOH PHARMA (03692.HK), is the wife of Hengrui Pharma's founder, Sun Piaoyang. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
